After the market close on Sept. 11, AstraZeneca reported that Etcamah failed to show progression-free survival benefit in SERENA-4, a Phase 3 trial in the upfront first-line setting for hormone receptor-positive, HER2-negative metastatic breast cancer patients.
The company has a healthy oncology portfolio, including Tagrisso, Imfinzi, Calquence, Enhertu, and Truqap, which looks well positioned to drive major cash flows over the next decade.
The company's strong entrenchment in respiratory disease could cause challenges, as pricing power in this market tends to be weak.
|
Metric
|
AZN
|
NVS
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.37 | 13.57 | 44.80 |
Price/Book Value | 4.86 | 6.45 | 8.47 |
Price/Sales | 4.02 | 4.80 | 5.36 |
Price/Cash Flow | 15.89 | 14.16 | 16.10 |
|
Metric
|
AZN
|
NVS
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.66 | 0.55 | 0.71 |
Current Ratio | 0.89 | 0.86 | 1.32 |
Interest Coverage | 7.99 | 11.90 | 4.28 |
|
Metric
|
AZN
|
NVS
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 9.00% | 14.74% | 6.27% |
Return on Equity (Normalized) | 21.69% | 39.06% | 16.68% |
Return on Invested Capital (Normalized) | 14.36% | 21.25% | 9.82% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|!L@^X&< | LOCK|&z | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|$m%>>N% | LOCK|M@Q | $623B | |||
| AbbVie Inc
ABBV
| LOCK|RFT<^< | LOCK|y% | $459B | |||
| Merck & Co Inc
MRK
| LOCK|?L$y<^? | LOCK|zN | $355B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|@q#bRH% | LOCK|kf? | $334B | |||
| Novartis AG ADR
NVS
| LOCK|TKdn<F>h | LOCK|p% | $268B | |||
| Amgen Inc
AMGN
| LOCK|XHD>JD!% | LOCK|^Y? | $220B | |||
| Gilead Sciences Inc
GILD
| LOCK|^!?wJ$h | LOCK|gpS | $183B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|@F#KMP | LOCK|jG> | $167B |
United States